The FINANCIAL — Takeda Pharmaceutical Company Limited on Janaury 6 announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc.
Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products, allowing the company to maximize global efficiencies and further enhance the product’s supply chain flexibility, according to Takeda.
“Takeda’s focus is providing patients access to quality therapies,” said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”
The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.
